logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
N

Nehal J. Lakhani

start center for cancer research
H指数:28
被引数:4,385
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer

Ib期临床试验：评估SL-172154（一种双特异性CD47抑制剂和CD40激动剂Fc融合蛋白）联合mirvetuximab soravtansine或脂质体多柔比星治疗铂耐药性卵巢癌患者的疗效。

British Journal of Cancer
IF6.8
2026-04-080
PRE
Yvette Drew; Lucy Gilbert; Alejandro Martinez Bueno; Ana Oaknin; Victor Moreno; Lydia Gaba Garcia; Gordon C. Jayson; Rebecca S. Kristeleit; Nehal Lakhani; Susana Banerjee; Daniela Matei; Amit Oza; Rowan Miller; Dennis Yiannakis; Maria-Pilar Barretina-Ginesta; Jerónimo Martínez García; Guanfang Wang; Jayalakshmi Miriyala; Amy Franke; Elisa Galvez; Lini Pandite; Debra L. Richardson
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer

首次人体I期临床试验，评估双特异性CD47抑制剂和CD40激动剂Fc融合蛋白SL-172154在铂耐药卵巢癌患者中的应用

JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2025-01-111
OA
Lakhani, Nehal J.; Stewart, Daphne; Richardson, Debra L.; Dockery, Lauren E.; Van Le, Linda; Call, Justin; Rangwala, Fatima; Wang, Guanfang; Ma, Bo; Metenou, Simon; Huguet, Jade; Offman, Elliot; Pandite, Lini; Hamilton, Erika
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

抗淋巴细胞活化基因3抗体Fianlimab与Cemiplimab在晚期恶性肿瘤患者中的首次人体剂量递增研究

CLINICAL CANCER RESEARCH
IF10.2
2024-10-180
OAAI
Lakhani, Nehal J.; Papadopoulos, Kyriakos P.; Johnson, Melissa Lynne; Park, Haeseong; Wang, Ding; Yap, Timothy A.; Dowlati, Afshin; Maki, Robert G.; Ulahannan, Susanna; Lynce, Filipa; Kelly, Karen; Williamson, Stephen; Malhotra, Jyoti; Chen, Shuquan; Gonzalez Ortiz, Ana; Jankovic, Vladimir; Paccaly, Anne; Masinde, Sheila; Mani, Jayakumar; Lowy, Israel; Gullo, Giuseppe; Sims, Tasha; Kroog, Glenn
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2024-08-131
OAAI
Cavalcante, Ludimila; Chandana, Sreenivasa; Lakhani, Nehal; Enstrom, Amanda; LeBlanc, Heidi; Schmalz, Joseph; Lengyel, Krisztina; Schneider, Frank; Thomas, Heather; Chisamore, Michael J.; Peng, Stanford L.; Naumovski, Allison; Davar, Diwakar
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

davoceticept (ALPN-202)，一种PD-L1-dependent的CD28共刺激物和双重PD-L1/CTLA-4抑制剂，作为单一疗法和与pembrolizumab联合治疗晚期实体瘤 (NEON-1和NEON-2) 的I期研究

JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2024-08-031
OAAI
Davar, Diwakar; Cavalcante, Ludimila; Lakhani, Nehal; Moser, Justin; Millward, Michael; Mckean, Meredith; Voskoboynik, Mark; Sanborn, Rachel E.; Grewal, Jaspreet S.; Narayan, Ajita; Patnaik, Amita; Gainor, Justin F.; Sznol, Mario; Enstrom, Amanda; Blanchfield, Lori; Leblanc, Heidi; Thomas, Heather; Chisamore, Michael J.; Peng, Stanford L.; Naumovski, Allison
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers
CANCER RESEARCH
IF16.6
2024-06-041
OAAI
Keller, Patricia J.; Adams, Elizabeth J.; Wu, Rentian; Cote, Alexandre; Arora, Shilpi; Cantone, Nico; Meyer, Rosana; Mertz, Jennifer A.; Gehling, Victor; Cui, Jike; Stuckey, Jacob I.; Khanna, Avinash; Zhao, Feng; Chen, Zehua; Yu, Ziyang; Cummings, Richard T.; Taimi, Mohammed; Lakhani, Nehal J.; Rasco, Drew; Gutierrez, Martin; Duska, Linda; Devitt, Michael; Rippley, Ronda; Levell, Julian; Truong, Jennifer; Wang, Jing; Sun, Kaiming; Trojer, Patrick
Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Moreno, Crystal; Flores, Johnnie; Simonson, Alyssa; DeBoer, Maci; Banos, Natalia; Diaz, Armando, III; Lynch, Morgan; Lund, Jim; Leykum, Leonora; Rouzbahan, Tahmi; Pedregal, Manuel; Papadopoulos, Kyriakos P.; Lang, Amy; Rosenthal, Arthur; Rasco, Drew; Rodriguez, Gladys; Rodriguez, Luis; Lakhani, Nehal; Beeram, Muralidhar; Patnaik, Amita; De Miguel, Maria; Drengler, Ronald; Abbate, Steven; Uribe, Bernard Doger de Speville; Wick, Michael
A phase 1b multicenter study of anti-TIM3 (S095018/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Ghiringhelli, Francois; Kim, Richard; Macarulla, Teresa; Moreno, Irene; Razak, Albiruni; Rodon, Jordi; Liao, Chih-Yi; Marron, Thomas; Raimbourg, Judith; Kaplon, Helene; Geromini, Julia; Harouki, Najah; Rodrigues, Christelle; Darcel, Pauline; Skartved, Niels Jorgen; Hald, Rikke; Lopez-Ravnborg, Daleen; He, Peng; Ianopoulos, Xenophon; Askoxylakis, Vasileios; Lakhani, Nehal J.; Davis, Sarah; Mahipal, Amit
Molecular and early clinical characterization of the anti-CD73 antibody S095024 (Sym024)
CANCER RESEARCH
IF16.6
2024-03-222
PRE
Spreafico, Anna; Ahnert, Jordi R.; Sommerhalder, David; Almena-Carrasco, Maria; Crochemore, Najah Harouki; Ianopulos, Xenophon; Jakobsen, Janus S.; Armbruster, Emily; Delmas, Audrey; Georges, Amedee des; Frohlich, Camilla; Geronimi, Julia; Grandal, Michael M.; Hansen, Randi W.; Lantto, Johan; Legrand, Julie; Levasseur, Franck; Riva, Matteo; Rodrigues, Christelle; Seif, Vanessa; Askoxylakis, Vasileios; Lakhani, Nehal
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
CLINICAL CANCER RESEARCH
IF10.2
2023-06-0216
OAAI
Subbiah, Vivek; Chawla, Sant P.; Conley, Anthony P.; Wilky, Breelyn A.; Tolcher, Anthony; Lakhani, Nehal J.; Berz, David; Andrianov, Vasily; Crago, William; Holcomb, Monica; Hussain, Abrahim; Veldstra, Carson; Kalabus, James; 'Neill, Brianne; Senne, Lane; Rowell, Emily; Heidt, Analeah B.; Willis, Katelyn M.; Eckelman, Brendan P.
Short or long-term treatment with CDK4/6 inhibitors in patients with ER plus breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models
CANCER RESEARCH
IF16.6
2023-04-041
PRE
Simonson, Alyssa; Flores, Johnnie; Lynch, Morgan; Carpenter, Emily; Hruzek, Justine; Lund, Jim; Herraiz, Natalia Banos; Papadopoulos, Kyriakos; Woude, Amy Vander; Rodriguez, Gladys; Chandana, Sreenivasa; Gribbin, Thomas; Lakhani, Nehal; Hernandez, Tatiana; de Miguel, Maria Jose; Lang, Amy; Wick, Michael J.

研究方向

暂未获取到该数据
A
Anthony W. Tolcher
H 指数:74论文数:934被引数:2.3万
A
Amita Patnaik
H 指数:77论文数:744被引数:3.5万
E
Elisa Fontana
H 指数:20论文数:216被引数:1,874
M
Meredith McKean
H 指数:22论文数:304被引数:3,069
S
Sreenivasa R Chandana
H 指数:22论文数:149被引数:2,853
J
Justin Call
H 指数:9论文数:88被引数:1,055
S
Stefan N. Symeonides
H 指数:25论文数:215被引数:3,737
G
Gerald S. Falchook
H 指数:68论文数:810被引数:2.6万
A
Alistair S. McLaren
H 指数:10论文数:75被引数:589
D
Drew Rasco
H 指数:41论文数:434被引数:8,310